Welcome to our dedicated page for Envveno Medical news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical stock.
enVVeno Medical Corporation develops bioprosthetic venous valve devices for severe deep chronic venous insufficiency in the United States. News about NVNO centers on the company’s enVVe System, a minimally invasive transcatheter replacement venous valve, and its TAVVE pivotal study under FDA investigational device exemption approval.
Recurring updates also cover the VenoValve surgical replacement venous valve, FDA communications tied to device review, clinical-development planning, cash runway and operating losses, Nasdaq listing compliance, shareholder-approved capital-structure actions such as the reverse stock split, and investor communications from this late clinical-stage medical device issuer.
Summary not available.
enVVeno Medical Corporation (NASDAQ: NVNO) has reported significant developments in its VenoValve and enVVe clinical programs. In 2022, the company achieved over half enrollment in the pivotal SAVVE trial of VenoValve, currently totaling 43 patients. The firm ended the year with $39.1 million in cash, remaining on track to sustain operations through the end of 2024. While Q4 cash burn was $3.6 million, net losses for the year declined to $16.5 million. Upcoming milestones include topline safety data from SAVVE expected before the end of 2023 and the initiation of the enVVe trial upon regulatory approval.
enVVeno Medical Corporation (NASDAQ:NVNO) will present at Cowen's 43rd Annual Health Care Conference on March 8, 2023, at 9:10 AM ET. During this event, CEO Robert Berman will discuss the company's innovative solutions for treating venous disease, highlighting their lead product, VenoValve, a first-in-class surgical replacement venous valve aimed at addressing Chronic Venous Insufficiency (CVI). The presentation will be accessible via a live video webcast on the company's website, available for 90 days post-event. enVVeno's advancements, including the upcoming TAVVE trial for their non-surgical enVVe valve, signify a commitment to improving venous care.
enVVeno Medical Corporation (Nasdaq: NVNO) has announced the promotion of Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer. Dr. Alavi has been instrumental in the development of enVVe, a transcatheter-based replacement venous valve, moving it from concept to readiness for human testing in a short timeframe. His role will now focus on integrating innovative technologies, such as artificial intelligence, into existing products and preparing for the commercialization of the VenoValve. These devices aim to improve treatment for chronic venous insufficiency (CVI), a condition affecting leg veins.
enVVeno Medical Corporation (NASDAQ:NVNO) announced promising results at the 49th Annual VEITH Symposium regarding its VenoValve clinical trial. Three years post-implantation, VenoValve recipients show no relapses of severe Chronic Venous Insufficiency (CVI) or venous ulcers. Average improvements in reflux, CVI manifestations, and pain are stable at 63%, 52%, and 84%, respectively. The trial involved eight patients with an average age of 68. The VenoValve aims to restore proper blood flow in patients with CVI, a condition affecting approximately 2.5 million people in the U.S.
enVVeno Medical Corporation announced the successful preliminary safety review by the FDA for its VenoValve, as part of the ongoing SAVVE U.S. pivotal study. The first 20 patients enrolled showed minimal adverse events, allowing the trial to proceed without changes. Currently, 33 patients are enrolled, with full enrollment expected by Q2 2023. The company reported $42.7 million in cash to sustain operations through 2024, including the upcoming release of pivotal trial data.
enVVeno Medical Corporation (NASDAQ:NVNO) reported its third-quarter 2022 financial results, ending with $42.7 million in cash and investments, providing a runway through 2024. The burn rate was $4.5 million for the quarter. Notably, the company is advancing its SAVVE pivotal trial with strong enrollment and is set to begin the TAVVE first-in-human study in early 2023. However, net losses increased to $6.1 million, up 154% year-over-year, primarily due to higher operating expenses, including a 140% rise in SG&A costs.
enVVeno Medical Corporation (NASDAQ:NVNO) announced CEO Rob Berman will participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, in New York, NY. Investors can join one-on-one meetings with management. A live video webcast will be available on the Company's website for 90 days post-event. enVVeno specializes in innovative solutions for venous disease, with its lead product, the VenoValve, in pivotal studies and awaiting approval for a non-surgical alternative, enVVe.
enVVeno Medical Corporation (NASDAQ: NVNO) will host a conference call and live audio webcast on September 21, 2022, at 4:30 PM ET. Interested parties can join by calling (877) 407-9708 (domestic) or (201) 689-8259 (international) using conference ID: 13732870. The live webcast will be available on the enVVeno website and archived for 90 days. The company focuses on innovative bioprosthetic solutions for venous disease, with its lead product, the VenoValve, currently in evaluation for treating Chronic Venous Insufficiency.
enVVeno Medical Corporation (Nasdaq: NVNO) announced CEO Robert Berman's participation at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022. The event will include virtual one-on-one meetings with investors. A video webcast of the presentation will be live from September 12 at 7:00 AM ET, with a replay available for 90 days on their website. enVVeno focuses on innovative solutions for venous disease, including its lead product, the VenoValve, which is currently evaluated in the SAVVE pivotal study.